This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Nektar (NKTR) Q3 Earnings & Revenues Top Estimates, Stock Up
by Zacks Equity Research
Nektar's (NKTR) reports encouraging third-quarter results. The company continues to progress with its pipeline candidates. However, the timeline for its pain drug NKTR-181's approval remains uncertain.
Allergan (AGN) Meets Q3 Earnings Estimates, Ups '19 Sales View
by Zacks Equity Research
Botox, Juveederm fillers, Vraylar drive Allergan's (AGN) third-quarter sales, making up for loss of exclusivity on some brands and lower sales of eye drug, Restasis.
Value Biotech ETFs & Stocks to Buy Now
by Sanghamitra Saha
Biotech valuation looks attractive amid a volley of good news. Investors can tap these stocks and ETFs.
What's in the Cards for Teva (TEVA) This Earnings Season?
by Zacks Equity Research
Pricing erosion in U.S. generics market and rapid erosion in sales of Copaxone are likely to have hurt Teva's (TEVA) Q3 sales
Agios' (AGIO) Q3 Loss Narrower Than Expected, Revenues Miss
by Zacks Equity Research
Although Agios (AGIO) betters loss estimates in Q3, its revenues lag the same. The company's wholly owned leukemia drug Tibsovo sees a rise in sales sequentially.
United Therapeutics (UTHR) Q3 Earnings & Sales Top, Stock Up
by Zacks Equity Research
United Therapeutics (UTHR) beats estimates on both fronts in the third quarter. Stock rises in response
Sanofi (SNY) Q3 Earnings Beat, Vaccines/CHC Units Hurt Sales
by Zacks Equity Research
Sanofi (SNY) reports mixed third-quarter results with strong Specialty Care sales but soft Vaccines & Consumer Healthcare sales.
Incyte (INCY) Beats on Q3 Earnings & Sales, Ups Jakafi View
by Zacks Equity Research
Incyte (INCY) reports better-than-expected results for the third quarter of 2019, owing to strong Jakafi sales.
Drug/Biotech Stock Q3 Earnings Due on Oct 29: MRK, PFE & More
by Zacks Equity Research
Four drug/biotech stocks are scheduled to release third-quarter results on Oct 29. Let's see how these companies are placed before their earnings call.
Pharma Stock Roundup: LLY, NVS, AZN's Q3 Earnings, Updates From FDA
by Kinjel Shah
Lilly (LLY), Novartis (NVS) and AstraZeneca (AZN) release Q3 results. FDA approves Glaxo's (GSK) Zejula and AstraZeneca's Farxiga for more patients. CHMP gives nod to several drugs
Lilly (LLY) Q3 Earnings Top Estimates, Sales Lag, Stock Down
by Zacks Equity Research
Eli Lilly's (LLY) Q3 earnings beat estimates while sales miss. Shares drop in pre-market trading.
Eli Lilly (LLY) Surpasses Q3 Earnings Estimates
by Zacks Equity Research
Lilly (LLY) delivered earnings and revenue surprises of 3.50% and -1.48%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stock Q3 Earnings on Oct 23: LLY, ALXN & More
by Zacks Equity Research
Four drug/biotech stocks are scheduled to release third-quarter results on Oct 23. Let's see how these companies are placed before their earnings call.
Pharma Stock Roundup: JNJ's Q3 Earnings, RHHBY's Sales, FDA Nod to Lilly's Reyvow
by Kinjel Shah
FDA approves Lilly's (LLY) lasmiditan oral tablets to treat acute migraine. J&J (JNJ) beats earnings and sales estimates in Q3
Lilly's Pancreatic Cancer Candidate Fails in Phase III Study
by Zacks Equity Research
Lilly's (LLY) immunotherapy candidate, pegilodecakin, falls short of meeting the primary endpoint of OS benefit in a phase III study investigating its usage in metastatic pancreatic cancer.
Can New Drugs Help Lilly (LLY) to Deliver Solid Q3 Earnings?
by Zacks Equity Research
Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are likely to have performed well. Let's see if these along with its older products lead to an earnings beat for the company in Q3.
Eli Lilly (LLY) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
This is Why Eli Lilly (LLY) is a Great Dividend Stock
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.
Lilly Gets FDA Approval for New Oral Tablets for Migraine
by Zacks Equity Research
Eli Lilly (LLY) gets FDA approval for lasmiditan oral tablets to treat acute migraine in adults.
Pharma Stock Roundup: NVS' New Eye Drug Gets FDA Nod, NVO, GSK, PFE Sign Deals
by Kinjel Shah
FDA approves Novartis' (NVS) Beovu. J&J (JNJ) files sBLA for Stelara. Pfizer (PFE), Novo Nordisk (NVO) and Glaxo (GSK) announce collaboration deals.
Gilead-Galapagos Report Efficacy & Safety Results on RA Drug
by Zacks Equity Research
Gilead (GILD) announces 52-week efficacy and safety results on experimental RA drug, filgotinib, from two late-stage studies.
3 Big Drug/Biotech Stocks Set to Beat Q3 Earnings Estimates
by Kinjel Shah
Here we highlight three bigshot drug/biotech companies, which are expected to deliver positive earnings surprises in Q3.
J&J (JNJ) to Start Q3 Earnings Season for Pharma Sector
by Zacks Equity Research
J&J's (JNJ) cancer drugs are expected to contribute significantly to third-quarter 2019 earnings. Generic/biosimilar headwinds are expected to hurt Pharma unit's sales.
Dermira Starts Lebrikizumab Dosing in Late-Stage Eczema Study
by Zacks Equity Research
Dermira (DERM) starts a phase III program for evaluation of its monoclonal antibody candidate, lebrikizumab, in adolescents and adult patients with atopic dermatitis, the most common form of eczema.
Gilead (GILD) Files NDA for RA Candidate Filgotinib in Japan
by Zacks Equity Research
Gilead's (GILD) new drug application for its JAK1 inhibitor filgotinib seeks treatment of rheumatoid arthritis in adult patients across Japan.